Research has shown that patients with CEL who have the FIP1L1-PDGFRα fusion gene may respond well to treatment with the tyrosine kinase inhibitor, imatinib [11,13]. The gene discussed is PDGFRA; the disease is Chronic Eosinophilic Leukemia, Not Otherwise Specified.